Published in Can J Kidney Health Dis on December 05, 2016
Inflammation, stress, and diabetes. J Clin Invest (2005) 17.11
Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest (2004) 13.42
Uric acid and cardiovascular risk. N Engl J Med (2008) 12.20
Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med (2005) 7.24
Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA (2000) 6.10
A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol (2005) 4.95
Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension (2001) 4.41
Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis (2006) 4.26
Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol (2010) 4.06
A role for uric acid in the progression of renal disease. J Am Soc Nephrol (2002) 3.77
The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes (2002) 3.15
Plasma malondialdehyde as biomarker for oxidative stress: reference interval and effects of life-style factors. Clin Chem (1997) 3.02
Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol (2007) 2.71
Childhood uric acid predicts adult blood pressure: the Bogalusa Heart Study. Hypertension (2004) 2.46
Thiazide diuretics exacerbate fructose-induced metabolic syndrome. J Am Soc Nephrol (2007) 2.24
Ten-year incidence of elevated blood pressure and its predictors: the CARDIA study. Coronary Artery Risk Development in (Young) Adults. J Hum Hypertens (1999) 2.17
Uric acid and the development of metabolic syndrome in women and men. Metabolism (2008) 2.09
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther (2010) 2.07
Leptin:adiponectin ratio is an independent predictor of intima media thickness of the common carotid artery. Stroke (2007) 2.04
Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes (2004) 1.92
Transforming growth factor-beta 1 hyperexpression in African-American hypertensives: A novel mediator of hypertension and/or target organ damage. Proc Natl Acad Sci U S A (2000) 1.86
Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol (2011) 1.85
Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes (2011) 1.82
Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial. Am J Kidney Dis (2015) 1.77
Plasma uric acid level and risk for incident hypertension among men. J Am Soc Nephrol (2006) 1.76
Allopurinol treatment and its effect on renal function in gout: a controlled study. Ann Rheum Dis (1982) 1.65
Increased renal production of transforming growth factor-beta1 in patients with type II diabetes. Diabetes (1997) 1.59
The role of uric acid in the pathogenesis of human cardiovascular disease. Heart (2013) 1.59
Circulating levels of TNF-alpha and IL-6-relation to truncal fat mass and muscle mass in healthy elderly individuals and in patients with type-2 diabetes. Mech Ageing Dev (2003) 1.50
The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey. Atherosclerosis (2003) 1.49
Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant (2013) 1.47
A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol (2011) 1.40
Association of hyperuricemia with renal outcomes, cardiovascular disease, and mortality. Clin J Am Soc Nephrol (2012) 1.29
Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients. Iran J Kidney Dis (2010) 1.23
Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes (2003) 1.23
Uric acid as a target of therapy in CKD. Am J Kidney Dis (2012) 1.22
High serum uric acid and increased risk of type 2 diabetes: a systemic review and meta-analysis of prospective cohort studies. PLoS One (2013) 1.17
Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia. Nephron Physiol (2008) 1.13
Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial. Kidney Blood Press Res (2011) 1.10
Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in non-diabetic, insulin-resistant subjects. Diabetologia (2004) 1.06
Uric acid and hypertension: cause or effect? Curr Rheumatol Rep (2010) 0.99
Circulating transforming growth factor-beta1 levels and the risk for kidney disease in African Americans. Kidney Int (2009) 0.98
Challenges of conducting a trial of uric-acid-lowering therapy in CKD. Nat Rev Nephrol (2011) 0.90
Urinary transforming growth factor-beta 1 in various types of nephropathy. Pharmacol Res (2004) 0.89
Low fat adiponectin expression is associated with oxidative stress in nondiabetic humans with chronic kidney disease--impact on plasma adiponectin concentration. Am J Physiol Regul Integr Comp Physiol (2007) 0.87
Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis. Clin Ther (2013) 0.87
Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy. J Med Assoc Thai (2006) 0.87
The interleukin-6 G(-174)C promoter polymorphism does not determine plasma interleukin-6 concentrations in experimental endotoxemia in humans. Clin Chem (2004) 0.83
Transforming growth factor beta and excess burden of renal disease. Trans Am Clin Climatol Assoc (2009) 0.82
Renal net acid excretion and plasma leptin are associated with potentially bioactive free glucocorticoids in healthy lean women. J Nutr (2008) 0.79
Thiobarbituric acid reactive substances are increased in the subcutaneous fat tissue of patients with end-stage renal disease. Nephrol Dial Transplant (1997) 0.76